Melanoma & Skin Cancer

Experts convened during an OncLive Scientific Interchange and Workshop to discuss evolving biomarker utilization and sequencing strategies in uveal melanoma.

Michael A. Postow, MD, discusses the current evidence gaps surrounding the management of irAEs in melanoma in the long term.

Michael A. Postow, MD, discusses the importance of multidisciplinary coordination following immune checkpoint inhibitor therapy completion for patients with melanoma.

Michael A. Postow, MD, discusses the significance of understanding how to identify late-onset irAEs and underlying comorbidities unrelated to treatment in melanoma.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.

Daniel Olson, MD, discusses findings with brenetafusp from a phase 1/2 trial (NCT04262466) in patients with advanced melanoma.

Frontline darovasertib plus crizotinib improved PFS vs investigator’s choice of therapy in patients with HLA-A*02:01–negative metastatic uveal melanoma.

Hirsch Matani, MD, Elizabeth Zhang-Velten, MD, PhD, and Binh T. Ngo, MD, discuss radiation and multidisciplinary approaches in skin cancer.

Replimune plans to resubmit a BLA for RP1 plus nivolumab after the FDA agreed to prioritize review due to the significant unmet need in advanced melanoma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

Beth N. McLellan, MD, discusses radiation dermatitis prevention, scalp cooling equity, and the future of personalized oncodermatology in melanoma management.

Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.

Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.

Here is your cheat sheet to all oncology therapeutic options that were cleared or rejected by the FDA in April 2026.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

iSCIB1+ has received fast track designation from the regulatory agency as a potential therapeutic options for patients with advanced melanoma.

The 5-year OS rate favored tebentafusp vs investigator’s choice of therapy in HLA-A*02:01–positive uveal melanoma.

Daniel Johnson, MD, discusses the use of TIL therapy in melanoma, including patient selection, sequencing, timing, and emerging applications beyond skin cancer.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

Frontline darovasertib plus crizotinib generated a PFS improvement vs treatment of investigator’s choice in HLA-A*02:01–negative metastatic uveal melanoma.

The FDA issued a CRL to RP1 plus nivolumab in advanced melanoma, accepted a NDA for the TLX101-Px imaging agent in glioma, and more.

The FDA issued a CRL to RP1 plus nivolumab for the management of advanced melanoma after progression on an anti–PD-1–containing regimen.